Trial Profile
A Phase III Trial to Compare the Safety and Efficacy of Intravenous UB-851 and Eprex With an Extension Safety Evaluation in Subjects With Renal Anemia on Hemodialysis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Epoetin alfa (Primary)
- Indications Anaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors UBI Pharma
- 29 Nov 2023 Status changed from not yet recruiting to completed.
- 17 Mar 2016 New trial record